https://scholars.lib.ntu.edu.tw/handle/123456789/641590
標題: | Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies | 作者: | Song, Yuqin SHANG-JU WU Shen, Zhixiang Zhao, Donglu Chan, Thomas Sau Yan Huang, Huiqiang Qiu, Lugui Li, Jianyong Tan, Tran-der Zhu, Jun Song, Yongping Huang, Wei-Han Zhao, Weili Liu, Herman Sung Yu Xu, Wei Chen, Naizhi Ma, Jun Chang, Cheng-Shyong Tse, Eric Wai Choi |
關鍵字: | BTK inhibitors; China; Consensus; Non-Hodgkin lymphoma; Targeted therapy | 公開日期: | 16-十月-2023 | 卷: | 12 | 期: | 1 | 起(迄)頁: | 92 | 來源出版物: | Experimental hematology & oncology | 摘要: | Targeted therapy with Bruton tyrosine kinase (BTK) inhibitors have revolutionized the treatment of patients with various B-cell malignancies. BTK inhibitors such as ibrutinib, zanubrutinib, orelabrutinib, and acalabrutinib have shown good clinical efficacy and better safety profiles than those of traditional chemotherapy and chemoimmunotherapy regimens. Multiple studies on new BTK inhibitors are ongoing, which may provide more therapeutic options for the treatment of B-cell malignancies. Considering the unmet need of evidence on BTK inhibitors in all clinical settings and to standardize the use of BTK inhibitors available in mainland China, Taiwan, Hong Kong, and Macau regions, this consensus has been formulated for the treatment of various B-cell malignancies based on the clinical practice and available evidences on the use of BTK inhibitors. The recommendations of this consensus will provide guidance to physicians and clinical researchers on the effective treatment of B-cell malignancies with BTK inhibitors. |
URI: | https://www.scopus.com/record/display.uri?eid=2-s2.0-85174264453&doi=10.1186%2fs40164-023-00448-5&origin=inward&txGid=a060f7a802d9374d331e9dfa9ac40704 https://scholars.lib.ntu.edu.tw/handle/123456789/641590 |
ISSN: | 2162-3619 | DOI: | 10.1186/s40164-023-00448-5 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。